S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
YIKES! 220 Pounds of Graphite in Each EV Battery? (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:CELU

Celularity - CELU Stock Forecast, Price & News

$1.79
+0.08 (+4.68%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.72
$1.85
50-Day Range
$1.42
$2.56
52-Week Range
$1.35
$13.19
Volume
352,024 shs
Average Volume
465,068 shs
Market Capitalization
$259.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Celularity MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
402.8% Upside
$9.00 Price Target
Short Interest
Healthy
3.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.14mentions of Celularity in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$86,800 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.73) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

374th out of 1,047 stocks

Pharmaceutical Preparations Industry

158th out of 512 stocks

CELU stock logo

About Celularity (NASDAQ:CELU) Stock

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Receive CELU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.

CELU Stock News Headlines

Celularity, Inc. (CELU) Q3 Earnings Beat Estimates
See More Headlines
Receive CELU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.

CELU Company Calendar

Last Earnings
11/12/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CELU
Fax
N/A
Employees
162
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+402.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-100,120,000.00
Pretax Margin
-76.25%

Debt

Sales & Book Value

Annual Sales
$21.33 million
Book Value
$1.13 per share

Miscellaneous

Free Float
89,763,000
Market Cap
$259.57 million
Optionable
Optionable
Beta
0.21

Key Executives

  • Dr. Robert Joseph Hariri M.D. (Age 63)
    Ph.D., Founder, CEO & Chairman
    Comp: $1.61M
  • Mr. John R. Haines (Age 65)
    Sr. EVP, GM & Chief Admin. Officer
    Comp: $561.17k
  • Mr. David C. Beers C.F.A. (Age 52)
    CFA, Chief Financial Officer
  • Dr. Bradley Glover Ph.D. (Age 53)
    Exec. VP & COO
  • Mr. Tim Wilk
    Sr. VP of Technical Operations
  • Carlos Ramirez
    SVP of Investor Relations
  • Mr. Keary R. Dunn Esq. (Age 52)
    EVP, Gen. Counsel, Chief Legal Officer & Head of Bus. Devel.
  • Ms. Beth Steinbrenner
    Exec. VP of HR
  • Dr. Stephen A. Brigido D.P.M. (Age 46)
    Pres of Degenerative Diseases
  • Dr. Anne Jones Ph.D. (Age 51)
    Exec. VP & Chief Bus. Officer













CELU Stock - Frequently Asked Questions

Should I buy or sell Celularity stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celularity in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CELU shares.
View CELU analyst ratings
or view top-rated stocks.

What is Celularity's stock price forecast for 2023?

5 Wall Street research analysts have issued 1-year price targets for Celularity's stock. Their CELU share price forecasts range from $5.00 to $15.00. On average, they predict the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 402.8% from the stock's current price.
View analysts price targets for CELU
or view top-rated stocks among Wall Street analysts.

How have CELU shares performed in 2022?

Celularity's stock was trading at $5.12 at the beginning of 2022. Since then, CELU stock has decreased by 65.0% and is now trading at $1.79.
View the best growth stocks for 2022 here
.

When is Celularity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our CELU earnings forecast
.

How were Celularity's earnings last quarter?

Celularity Inc. (NASDAQ:CELU) posted its earnings results on Friday, November, 12th. The company reported $0.40 EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.75. The company had revenue of $10.62 million for the quarter, compared to analysts' expectations of $3.46 million. Celularity had a negative trailing twelve-month return on equity of 45.65% and a negative net margin of 76.36%.

What is Celularity's stock symbol?

Celularity trades on the NASDAQ under the ticker symbol "CELU."

Who are Celularity's major shareholders?

Celularity's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.51%), Vanguard Group Inc. (2.16%), State Street Corp (0.44%), B. Riley Financial Inc. (0.27%), Bank of New York Mellon Corp (0.14%) and Nuveen Asset Management LLC (0.14%).
View institutional ownership trends
.

How do I buy shares of Celularity?

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celularity's stock price today?

One share of CELU stock can currently be purchased for approximately $1.79.

How much money does Celularity make?

Celularity (NASDAQ:CELU) has a market capitalization of $259.57 million and generates $21.33 million in revenue each year. The company earns $-100,120,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does Celularity have?

The company employs 162 workers across the globe.

How can I contact Celularity?

Celularity's mailing address is 1325 AVENUE OF THE AMERICAS 25TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.celularity.com. The company can be reached via phone at 908-768-2170.

This page (NASDAQ:CELU) was last updated on 12/2/2022 by MarketBeat.com Staff